Cangrelor tetrasodium and Frovatriptan Succinate

• Generic Name: cangrelor
• Dosage Forms: n.a.
• Other Brand Names: Kengreal

Used as an adjunct to PCI to reduce the risk of periprocedural MI, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12-receptor antagonist and are not being given a glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor.

Dual-drug antiplatelet therapy with a P2Y12-receptor antagonist and aspirin is part of the current standard of care in patients with acute coronary syndromes (ACS).

Potential advantages of cangrelor include rapid onset and offset of effect and less interindividual variability in antiplatelet effect (i.e., compared with clopidogrel).

Precise role of cangrelor in the management of ACS remains to be established.

• Generic Name: frovatriptan
• Dosage Forms: n.a.
• Other Brand Names: Frova

Acute treatment of migraine attacks with or without aura.

Not recommended for management of hemiplegic or basilar migraine or for prophylaxis of migraine.

Safety and efficacy not established for management of cluster headaches.